Type 2 Diabetes

SURPASS-CVOT showed tirzepatide is non-inferior to dulaglutide for cardiovascular events in more than 13,000 adults with type 2 diabetes.

Abbott's Libre Duo 10 Day earned FDA De Novo authorization, becoming the first continuous dual glucose-ketone monitor for diabetes.

A new study from the AHA has indicated the real prevalence of CKM syndrome stages 0-3 in young adults in their 20s.

A recent study has shown that a significantly greater proportion of patients with HF were correctly identified when testing NT-proBNP levels.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss new insulin pump technology presented at ADCES 2026.

Novo Nordisk's once-weekly insulin icodec-abae (Awiqli) has launched nationwide for adults with type 2 diabetes.

Diabetes Dialogue hosts recap ADCES26 highlights on insulin delivery tech, CKM care, C-peptide science, ketone monitoring, and hypercortisolism screening.

In a trial comparing tirzepatide initiation with sitagliptin, the GLP-1/glucose dual agonist displayed greater reductions in major cardiovascular events.

The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.

Limits to provider taxes used to fund Medicaid programs, as well as increased eligibility requirements and cost-sharing obligations, may make insurance inaccessible.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline data from the TRIUMPH-3 trial of retatrutide.

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

New Drug Applications and key trial readouts punctuated July for endocrinology, with treatments for hypocalcemia, diabetes, and more.

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Elena Christofides, MD, discusses the interim results of CAPTAIN-T2D, a trial that plans to evaluate clofutriben’s efficacy in these patients.

ENDO 2026 data suggest tirzepatide may improve renal transplant eligibility in patients with T2D, CKD, and severe obesity.

At ENDO 2026, findings suggest SBP reductions in adults with diabetes are driven by weight loss, not GLP-1 therapy type.